RxDoctor Payments Data

Peter Burke, MD

Cardiovascular Disease · Lansing, MINPI 1770605198

Payments from drug & device makers

$126,663in general payments, 2019–2025

Across 661 payments — averaging $191.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$61K
  • Stryker$33K
  • Johnson & Johnson$21K
  • Medtronic$5K
  • Novartis$731
  • Amgen$693
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$19,21052%
  • Travel & lodging$6,78118%
  • Food & beverage$10,74229%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,663 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$121,342
Medicare patients
776
Services billed
1,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$329,037
XareltoRivaroxaban181$196,392
JardianceEmpagliflozin121$122,428
Repatha SureclickEvolocumab72$87,281
EntrestoSacubitril/Valsartan45$52,682
FarxigaDapagliflozin Propanediol45$49,055
Praluent PenAlirocumab22$24,533
Repatha SyringeEvolocumab19$20,943
OzempicSemaglutide11$19,688
MultaqDronedarone Hcl11$17,671
Flecainide Acetate82$6,184
Metoprolol Succinate333$5,981
Rosuvastatin Calcium201$4,949
Atorvastatin Calcium246$4,741
Ezetimibe148$4,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$576$329,037278 claims
Johnson & JohnsonXarelto$20,643$196,392181 claims
Boehringer IngelheimJardiance$551$122,428121 claims
NovartisEntresto$731$52,68245 claims
AstraZenecaFarxiga$550$49,05545 claims
Novo NordiskOzempic$86$19,68811 claims
Sanofi-aventis U.S. LLCMultaq$191$17,67111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →